



(43) International Publication Date
20 December 2012 (20.12.2012)

(10) International Publication Number
WO 2012/172345 A3

(51) International Patent Classification:

C07K 14/52 (2006.01) *G01N 33/48* (2006.01)
A61M 1/36 (2006.01) *C07K 17/02* (2006.01)
B01J 20/32 (2006.01)

(21) International Application Number:

PCT/GB2012/051355

(22) International Filing Date:

13 June 2012 (13.06.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/496,195 13 June 2011 (13.06.2011) US

(71) Applicant (for all designated States except US): **ITH IMMUNE THERAPY HOLDINGS** [SE/SE]; Unit L2:04, Karolinska University Hospital Solna, S-171 76 Stockholm (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COTTON, Graham** [GB/GB]; 18 Dreghorn Park, Edinburgh EH13 9PH (GB). **WINQVIST, Ola** [SE/SE]; Svanckarrsvagen 32-F, S-756 53 Uppsala (SE).

(74) Agent: **SPENCER, Matthew**; Verulam Gardens, 70 Gray's Inn Road, London, Greater London WC1X 8BT (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

7 March 2013

(54) Title: TREATING CONDITIONS ASSOCIATED WITH ALLERGY

(57) Abstract: A method for treating an allergic condition comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising a binding reagent capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR3, CXCR1, CXCR2 and/or CCR2 immobilized directly or indirectly on the support thus removing chemokine receptor, optionally CCR3, CXCR1, CXCR2 and/or CCR2 expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.



WO 2012/172345 A3

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2012/051355

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07K14/52 A61M1/36 B01J20/32 G01N33/48 C07K17/02
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K A61M B01J G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DE 10 2005 036505 A1 (ADEXTER GMBH [DE]) 1 June 2006 (2006-06-01) paragraph [2324] -----	4, 13, 35-42
Y	WO 2007/133147 A1 (IBD COLUMN THERAPIES INTERNAT [SE]; THOERN MAGNUS [SE]; WINQVIST OLA [] 22 November 2007 (2007-11-22) claims -----	4, 13, 35-42
Y	WO 2010/029317 A2 (IBD COLUMN THERAPIES INTERNAT [SE]; WINQVIST OLA [SE]; COTTON GRAHAM [] 18 March 2010 (2010-03-18) cited in the application the whole document ----- -/-	1-18, 35-42

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21 September 2012

Date of mailing of the international search report

11/01/2013

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Van der Schaal, C

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2012/051355

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2003/017979 A1 (MACK MATTHIAS [DE] ET AL) 23 January 2003 (2003-01-23) claims 4, 5, 19 -----	4, 13, 35-42
Y	WO 2008/059066 A1 (HAEMOPEP PHARMA GMBH [DE]; ESCHER SYLVIA [DE]; ELSNER JOERN [DE]; FORS) 22 May 2008 (2008-05-22) page 5, line 25 - line 28 -----	1-18, 35-42
Y	NIKHIL YAWALKAR ET AL: "Enhanced Expression of Eotaxin and CCR3 in Atopic Dermatitis", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 113, no. 1, 1 July 1999 (1999-07-01), pages 43-48, XP055038047, ISSN: 0022-202X, DOI: 10.1046/j.1523-1747.1999.00619.x the whole document -----	1-18, 35-42
Y	T J Williams ET AL: "Eotaxin and CCR3 as therapeutic targets in asthma and allergy", Chemokines 2, 1 January 2003 (2003-01-01), XP055038313, Paris Retrieved from the Internet: URL: http://www.pasteur.fr/applications/euroconf/chemokines2/Williams.pdf [retrieved on 2012-09-17] the whole document -----	1-18, 35-42
Y	DAVID CHANTRY ET AL: "Chemokines in Allergy", CURRENT DRUG TARGETS- INFLAMMATION & ALLERGY, vol. 1, no. 1, 1 January 2002 (2002-01-01) , pages 109-116, XP055038300, abstract -----	1-18, 35-42
Y	PEASE JAMES E: "Asthma, allergy and chemokines", CURRENT DRUG TARGETS, BENTHAM SCIENCE PUBLISHER, US Current Drug targets, vol. 7, no. 1 1 January 2006 (2006-01-01), pages 3-12, XP008156147, ISSN: 1389-4501 Retrieved from the Internet: URL: http://www.benthamdirect.org/pages/article/1/117/asthma-allergy-and-chemokines.html [retrieved on 2012-09-13] page 111 - left-hand column -----	1-18, 35-42

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2012/051355

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-18, 35-42(all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-18, 35-42(all partially)

A binding reagent capable of specifically binding the CCR3 chemokine receptor, immobilized on a solid support within an apheresis column, and its use for treating allergic conditions

2. claims: 1-18, 35-42(all partially)

A binding reagent capable of specifically binding the CXCR1 chemokine receptor, immobilized on a solid support within an apheresis column, and its use for treating allergic conditions

3. claims: 1-18, 35-42(all partially)

A binding reagent capable of specifically binding the CXCR2 chemokine receptor, immobilized on a solid support within an apheresis column, and its use for treating allergic conditions

4. claims: 1-18, 35-42(all partially)

A binding reagent capable of specifically binding the CCR2 chemokine receptor, immobilized on a solid support within an apheresis column, and its use for treating allergic conditions

5. claims: 19-29

Methods of diagnosing allergic conditions or selecting a suitable treatment for the disease comprising determining the levels of CCR3, CXCR1, CXCR2 and/or CCR2

6. claims: 30-34, 57-61

Modified CCL11/eotaxin chemokine

7. claims: 43-47

Modified CCL8/MCP-2 chemokine

8. claims: 48-51

Modified CCL5/RANTES chemokine

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

9. claims: 52-56

Modified CCL2/MCP-1 chemokine

10. claims: 62-67

Modified CXCL8 chemokine

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2012/051355

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 102005036505 A1	01-06-2006	NONE	

WO 2007133147 A1	22-11-2007	AU 2007250552 A1	22-11-2007
		CA 2651883 A1	22-11-2007
		CN 101443041 A	27-05-2009
		EA 200802086 A1	30-06-2009
		EP 2021025 A1	11-02-2009
		JP 2009536944 A	22-10-2009
		KR 20090007642 A	19-01-2009
		SG 171684 A1	29-06-2011
		US 2009192434 A1	30-07-2009
		WO 2007133147 A1	22-11-2007
		ZA 200809429 A	26-08-2009

WO 2010029317 A2	18-03-2010	AU 2009290694 A1	18-03-2010
		CA 2736632 A1	18-03-2010
		CN 102186880 A	14-09-2011
		EA 201100452 A1	30-12-2011
		EP 2331568 A2	15-06-2011
		JP 2012501708 A	26-01-2012
		KR 20110057222 A	31-05-2011
		US 2011224645 A1	15-09-2011
		WO 2010029317 A2	18-03-2010

US 2003017979 A1	23-01-2003	US 2003017979 A1	23-01-2003
		US 2005191702 A1	01-09-2005

WO 2008059066 A1	22-05-2008	NONE	
